Current Advances in the Prevention, Risk, and Management of Infection in Patients Receiving Biologic Therapy for Dermatologic Disorders

Cory A. Kosche, Yasmeen Ali, Anna C. Figueiredo, Dennis P West, Beatrice Nardone*

*Corresponding author for this work

Research output: Contribution to journalReview article


Purpose of Review: Biologic agents such as adalimumab, etanercept, golimumab, certolizumab, ustekinumab, brodalumab, secukinumab, ixekizumab, dupilumab, alefacept, rituximab, omalizumab, tildrakizumab, and guselkumab are now indicated in the treatment of dermatologic disorders. This review reports on current prevention, risk, and management of infection in patients receiving biologic therapy for dermatologic disorders. Recent Findings: Although risk of infection in patients receiving biologic agents for management of a dermatologic disorder is well-known, it appears to continue to be a low risk. However, optimal prevention and management of some infection risks remain an unmet need. Summary: Although the overall risk for infection during biologic therapy for dermatologic disorders appears to remain low, there remains concern about the level of risk for reactivation of tuberculosis, as well as hepatitis B and C, and the risk for other, often uncommon, serious infection remains unknown. Continued pharmacovigilance serves to mitigate risk as well as promote optimal management of dermatologic disorders with biologic agents.

Original languageEnglish (US)
Pages (from-to)141-148
Number of pages8
JournalCurrent Dermatology Reports
Issue number3
StatePublished - Sep 15 2019



  • Adverse events
  • Biologic agents
  • Dermatologic disorders
  • Infections
  • Infectious disease
  • Safety

ASJC Scopus subject areas

  • Dermatology

Cite this